SCHEMBL4886470

SCHEMBL4886470

O=C(O)C[C@@H](CCc1ccc(Cl)cc1)NCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAAT3 P53816 2/20 0.50
PLAAT5 Q96KN8 2/20 0.50
PLAAT2 Q9NWW9 2/20 0.50
PLAAT4 Q9UL19 2/20 0.50
LMNA P02545 2/20 0.50
ALDH1A1 P00352 1/20 0.50
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
FFAR1 O14842 1/20 0.46
DPP7 Q9UHL4 2/20 0.46
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP12 P39900 1/20 0.44
MMP13 P45452 1/20 0.44
MMP14 P50281 1/20 0.44
GABRB1 P18505 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886478 1.00 PLAAT3 (0.50) PLAAT3PLAAT5PLAAT2PLAAT4LMNA
SCHEMBL4888749 1.00 PLAAT3 (0.50) PLAAT3PLAAT5PLAAT2PLAAT4LMNA
SCHEMBL4878019 0.91 CTSG (0.48) ALDH1A1FFAR1MEN1KMT2AMMP2
SCHEMBL4879353 0.91 CTSG (0.48) ALDH1A1FFAR1MEN1KMT2AMMP2
SCHEMBL4878013 0.91 CTSG (0.48) ALDH1A1FFAR1MEN1KMT2AMMP2
SCHEMBL4850843 0.87 CTSG (0.47) PLAAT3PLAAT5PLAAT2PLAAT4LMNA
SCHEMBL4886817 0.86 ALDH1A1 (0.52) PLAAT3PLAAT5PLAAT2PLAAT4LMNA
SCHEMBL4882026 0.86 ALDH1A1 (0.52) PLAAT3PLAAT5PLAAT2PLAAT4LMNA
SCHEMBL4882016 0.86 ALDH1A1 (0.52) PLAAT3PLAAT5PLAAT2PLAAT4LMNA
SCHEMBL4878562 0.86 DPP7 (0.56) PLAAT3PLAAT5PLAAT2PLAAT4PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1493819-B1 PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER UBE INDUSTRIES (JP) 2014-11-12 EP disclosed
US-7449325-B2 Process for enzymatically producing either optically active N-substituted β-amino acids or esters thereof or optically active N-substituted 2-homopipecolic acids or esters thereof UBE INDUSTRIES, LTD. (JP) 2008-11-11 US disclosed
US-20050170473-A1 Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester UBE INDUSTRIES, LTD. (JP) 2005-08-04 US disclosed
EP-1493819-A1 PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER Ube Industries, Ltd. (JP) 2005-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050170473-A1 Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester CYP8B1, SRR, HM13 PLAAT3 319/4885PLAAT5 801/4885PLAAT2 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.